The purpose of this study is to evaluate whether there is a difference in proportion of patients with resolution of heartburn and other symptoms related to gastroesophageal reflux disease (GERD) after four weeks of treatment with esomeprazole (NEXIUM®) in those subjects with Erosive Esophagitis (EE) and those without EE.

Condition	Intervention	Phase
GERD	Drug: Esomeprazole	Phase IV

Further study details as provided by AstraZeneca:

Primary Outcomes: The outcome variable will be the percentage of patients with heartburn resolution stratified by the presence or absence of EE
Secondary Outcomes: 1. The outcome variables will be resolution of acid regurgitation, dysphagia, and epigastric pain symptoms after 2 and 4 weeks of treatment.; 2. The outcome variable will be the resolution of heartburn after 2 weeks of treatment.; 3. The outcome variables will be the presence or absence of EE at baseline and the resolution of heartburn at the end of the 4-week treatment period.; 4. The outcome variable used for this objective will be the percentage of endoscoped patients with EE (LA Classification Grades A-D) at baseline.; 5. Safety variables that will be measured and tabulated include adverse events, laboratory evaluations, physical exams, and vital signs.
Expected Total Enrollment:  350

Ages Eligible for Study:  18 Years   -   70 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Symptoms of GERD as defined in this protocol: Heartburn (severity of mild, moderate or severe) 2 or more times in the 7 days prior to the Screening visit (Visit 1) and, on average, at least 2 times per week over the past 3 months.
• Male or female, 18 to 70 years old, inclusive.
• Non-pregnant, non-lactating female patients. Female patients must be postmenopausal, surgically sterile, or using a medically acceptable form of birth control, as determined by the investigator. Females of childbearing potential must agree to continue using an acceptable form of birth control throughout the conduct of the study.
• Negative urine pregnancy test for females of childbearing potential.
• Willingness to adhere to all protocol requirements.

Exclusion Criteria:

• Previous enrollment in the present study.
• Significant clinical illness within 2 weeks prior to the first dose of study medication or a significant illness during the study.
• Use of a PPI, including PRILOSEC OTC®, within 21 days of Screening (Visit 1) or at anytime during the study (Visit 1 through Visit 4).
• Daily therapy with an H2 RA within 14 days of Screening (Visit 1): eg, ranitidine (ZANTAC®), cimetidine (TAGAMET®), nizatidine (AXID®), famotidine (PEPCID®) (occasional use; ie, less than daily, is permitted).
• Use of H2 RAs at any frequency are prohibited throughout the entire study (Visit 1 through Visit 4).
• A history of gastric or esophageal surgery (including, but not limited to, Nissen fundoplication and bariatric surgery), except for simple closure of a perforated ulcer or procedures that would not affect the study as determined by the Clinical Study Team physician at AstraZeneca.
• Clinically significant gastrointestinal (GI) bleeding (eg, melena, frank hematochezia) within 3 days of Screening (Visit 1) or noted at the time of baseline EGD.
• Non-acid related etiologies of esophagitis (eg, pill-induced, caustic ingestion or eosinophilic esophagitis).

Generalized bleeding disorders resulting from hemorrhagic diathesis (such as abnormalities in clotting factors or platelets).

Please refer to this study by ClinicalTrials.gov identifier  NCT00242736

AstraZeneca Information, (US - 8a-7p EST)      800-236-9933    http://www.informationcenter@astrazeneca.com

Alabama
      Research Site, Mobile,  Alabama,  United States
      Research Site, Alabaster,  Alabama,  United States
Arizona
      Research Site, Tucson,  Arizona,  United States
Arkansas
      Research Site, North Little Rock,  Arkansas,  United States
California
      Research Site, Orange,  California,  United States
      Research Site, Torrance,  California,  United States
      Research Site, Anaheim,  California,  United States
Florida
      Research Site, Ocoee,  Florida,  United States
      Research Site, Zephyrhills,  Florida,  United States
      Research Site, Miami,  Florida,  United States
      Research Site, Tampa,  Florida,  United States
Illinois
      Research Site, Arlington Heights,  Illinois,  United States
Louisiana
      Research Site, New Orleans,  Louisiana,  United States
      Research Site, Shreveport,  Louisiana,  United States
Maryland
      Research Site, Hollywood,  Maryland,  United States
North Carolina
      Research Site, Elkin,  North Carolina,  United States
Oklahoma
      Research Site, Oklahoma City,  Oklahoma,  United States
Tennessee
      Research Site, Chattanooga,  Tennessee,  United States
      Research Site, Knoxville,  Tennessee,  United States
Texas
      Research Site, Houston,  Texas,  United States
      Research Site, Austin,  Texas,  United States
Utah
      Research Site, Salt Lake City,  Utah,  United States
      Research Site, Ogden,  Utah,  United States
Virginia
      Research Site, Christiansburg,  Virginia,  United States
      Research Site, Norfolk,  Virginia,  United States

Study chairs or principal investigators

AstraZeneca Nexium Medical Sciences Director, MD,  Study Director,  AstraZeneca   

Study ID Numbers:  D9612L00083
Last Updated:  December 8, 2005
Record first received:  October 19, 2005
ClinicalTrials.gov Identifier:  NCT00242736
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2006-01-10